Insider trading

Period: 120 months Stock: ANIP Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

115 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

115 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

115 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

115 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
115 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
115 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

115 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
10 Aug 2026
Gutwerg Ori SVP, GENERICS
Sold at will
$243.47K 3,162 at 77.00
4.0%
Not planned
13 May 2026
Walsh Patrick D Director
Sold at will
$806.30K 10,000 at 80.63
20.6%
Not planned
12 May 2026
Gutwerg Ori SVP, GENERICS
Sold at will
$220.37K 2,772 at 79.50
3.4%
Not planned
12 May 2026
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS
Sold at will
$36.36K 459 at 79.21
1.2%
Not planned
11 May 2026
Lalwani Nikhil PRESIDENT & CEO
Sold at will
$4.27M 55,000 at 77.57
13.6%
Not planned
11 May 2026
Walsh Patrick D Director
Sold at will
$320.82K 3,973 at 80.75
7.6%
Not planned
11 Mar 2026
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS
Sold at will
$357.47K 4,772 at 74.91
11.0%
Not planned
5 Mar 2026
CAREY STEPHEN P. SVP & CFO
Sold at will 2×
$552.03K 7,312 at 75.50
3.8%
Not planned
3 Mar 2026
Walsh Patrick D Director
Sold at will
$445.38K 6,000 at 74.23
10.3%
Not planned
3 Mar 2026
Gutwerg Ori SVP, GENERICS
Sold at will
$157.59K 2,060 at 76.50
2.4%
Not planned
5 Dec 2025
Sold at will
$146.07K 1,800 at 81.15
6.7%
Not planned
13 Nov 2025
Walsh Patrick D Director
Sold at will
$750.90K 8,643 at 86.88
12.3%
Not planned
13 Nov 2025
Gassert Chad SVP - CORP. DEV. & STRATEGY · indirect
Sold at will
$8.27K 94 at 88.00
0.1%
Not planned
12 Nov 2025
Gassert Chad SVP - CORP. DEV. & STRATEGY · indirect
Sold at will
$1.30M 14,642 at 89.07
8.5%
Not planned
3 Sep 2025
Pera Antonio R Director
Sold at will
$692.30K 7,292 at 94.94
24.3%
Not planned
25 Aug 2025
Sold at will
$229.09K 2,528 at 90.62
26.9%
Not planned
22 Aug 2025
Davis Krista SVP, CHIEF HR OFFICER
Sold at will
$160.61K 1,763 at 91.10
2.7%
Not planned
21 Aug 2025
Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS · indirect
Sold at will
$4.79M 52,988 at 90.44
10.9%
Not planned
20 Aug 2025
Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS · indirect
Sold at will
$4.24M 47,012 at 90.27
8.8%
Not planned
20 Aug 2025
Pera Antonio R Director
Sold at will
$486.43K 5,421 at 89.73
15.3%
Not planned
18 Aug 2025
Thoma Jeanne Director
Sold at will 2×
$1.92M 21,540 at 89.15
47.9%
Not planned
18 Aug 2025
Sold at will
$611.64K 6,937 at 88.17
42.5%
Not planned
15 Aug 2025
Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS · indirect
Sold at will
$4.62M 52,990 at 87.15
9.1%
Not planned
15 Aug 2025
Gassert Chad SVP - CORP. DEV. & STRATEGY · indirect
Sold at will
$1.74M 20,000 at 86.97
10.4%
Not planned
15 Aug 2025
Walsh Patrick D Director
Sold at will
$801.45K 9,000 at 89.05
11.4%
Not planned
14 Aug 2025
Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS · indirect
Sold at will
$4.21M 47,010 at 89.48
7.4%
Not planned
12 Aug 2025
Lalwani Nikhil PRESIDENT & CEO
Sold at will
$4.89M 56,960 at 85.93
12.2%
Not planned
12 Aug 2025
CAREY STEPHEN P. SVP & CFO
Sold at will
$4.30M 50,000 at 86.07
21.7%
Not planned
12 Aug 2025
HAUGHEY THOMAS Director
Sold at will
$1.66M 19,341 at 85.93
34.6%
Not planned
12 Aug 2025
Gutwerg Ori SVP, GENERICS
Sold at will
$508.19K 5,873 at 86.53
6.5%
Not planned
12 Aug 2025
Rowland Thomas Andrew SVP, HEAD - ESTABLISHED BRANDS
Sold at will
$426.41K 4,975 at 85.71
10.9%
Not planned
15 May 2025
Gutwerg Ori SVP, GENERICS
Sold at will
$52.92K 881 at 60.07
1.0%
Not planned
14 May 2025
Mutz Christopher HEAD OF RARE DISEASE
Sold at will
$241.80K 4,000 at 60.45
3.6%
Not planned
5 Mar 2025
Gutwerg Ori SVP, GENERICS
Sold at will 2×
$323.05K 5,384 at 60.00
5.4%
Not planned
17 Dec 2024
CAREY STEPHEN P. SVP & CFO
Sold at will
$418.43K 7,500 at 55.79
4.6%
Not planned
26 Nov 2024
Lalwani Nikhil PRESIDENT & CEO
Sold at will 2×
$1.94M 33,481 at 57.99
8.3%
Not planned
15 Nov 2024
Mutz Christopher HEAD OF RARE DISEASE
Sold at will
$375.05K 6,500 at 57.70
7.8%
Not planned
5 Jun 2024
Gutwerg Ori SVP, GENERICS
Sold at will
$200.00K 2,985 at 67.00
3.7%
Not planned
4 Jun 2024
CAREY STEPHEN P. SVP & CFO
Sold at will
$317.90K 5,000 at 63.58
3.0%
Not planned
21 May 2024
Mutz Christopher HEAD OF RARE DISEASE
Sold at will
$123.22K 2,000 at 61.61
2.3%
Not planned
16 May 2024
Sold at will
$127.74K 2,000 at 63.87
9.9%
Not planned
14 May 2024
Lalwani Nikhil PRESIDENT & CEO
Sold at will
$1.10M 16,669 at 66.10
4.2%
Not planned
11 Mar 2024
CAREY STEPHEN P. SVP & CFO
Sold at will
$510.44K 7,787 at 65.55
4.2%
Not planned
8 Mar 2024
Lalwani Nikhil PRESIDENT & CEO
Sold at will
$1.09M 16,292 at 67.13
3.8%
Not planned
7 Mar 2024
Marken James G. SVP OPS & PROD DEV
Sold at will
$1.62M 24,338 at 66.37
16.4%
Not planned
6 Mar 2024
Lalwani Nikhil PRESIDENT & CEO
Sold at will
$1.90M 28,965 at 65.52
6.1%
Not planned
5 Mar 2024
Mutz Christopher HEAD OF RARE DISEASE
Sold at will
$330.00K 5,000 at 66.00
5.4%
Not planned
4 Mar 2024
Pera Antonio R Director
Sold at will
$456.40K 7,000 at 65.20
20.8%
Not planned
15 Nov 2023
Davis Krista SVP, CHIEF HR OFFICER
Sold at will
$141.09K 2,622 at 53.81
7.4%
Not planned
10 Nov 2023
Mutz Christopher HEAD OF RARE DISEASE
Sold at will
$157.41K 3,000 at 52.47
4.5%
Not planned
Showing 1–50 of 115. Page 1 of 3 Older →